Tier 2 — strong

Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials

Linggen Gao, Qunxia Mao, Jian Cao, Yutang Wang, Xianliang Zhou, Li Fan
Atherosclerosis 2012 221(2):311-316

Bibliography

PubMed
PMID 22088605
DOI
10.1016/j.atherosclerosis.2011.10.027
Funding
Specific funding was not identified in the accessible PubMed/ScienceDirect record checked during this audit.
Competing interests
A specific conflict-of-interest statement was not identified in the accessible article record checked during this audit.

Study snapshot

DesignMeta-analysis of randomized controlled trials
ModelMeta-analysis of randomized controlled trials comparing CoQ10 with placebo for peripheral endothelial function in people with and without established cardiovascular disease.
Sample5 randomized trials; 194 participants (97 allocated to CoQ10 and 97 to control across the pooled trials).
InterventionCoQ10 supplementation versus placebo; the included trials were randomized and double-blind, but doses, populations and treatment protocols varied.
Duration
EndpointsFlow-mediated dilation (FMD); Nitrate-mediated dilation (NMD); Endothelial function; Heterogeneity across randomized trials

What the study showed, in plain terms

This early meta-analysis pooled five randomized controlled trials with 194 participants to evaluate CoQ10 and arterial endothelial function. It found a large standardized improvement in flow-mediated dilation (FMD), which reflects endothelium-dependent vasodilation.

FMD favored CoQ10 (SMD 1.70, 95% CI 1.00–2.40; p<0.0001). Nitrate-mediated dilation, which is less dependent on endothelial nitric-oxide signaling, did not improve significantly (SMD -0.19, 95% CI -1.75 to 1.38; p=0.81).

The pattern is biologically coherent with an endothelial-specific effect, but the evidence base was very small and centered on surrogate vascular physiology rather than clinical cardiovascular events.

Key findings

FMD: SMD 1.70, 95% CI 1.00–2.40, p<0.0001, favoring CoQ10.

Nitrate-mediated dilation: SMD -0.19, 95% CI -1.75 to 1.38, p=0.81—no significant effect.

Evidence base: only five eligible randomized trials and 194 total participants.

Clinical meaning: the study supports a possible improvement in endothelial-dependent vascular responsiveness; it does not establish effects on hypertension outcomes, myocardial infarction, stroke or mortality.

What this study can and cannot tell us

Very small evidence base: five trials and 194 participants.

Included populations differed in cardiovascular status, and dosing/formulation details were not uniform.

FMD and NMD are surrogate physiological endpoints, not clinical events.

The review searched literature only through July 2011, so it should be interpreted as an early evidence synthesis rather than the current totality of endothelial-function evidence.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology